• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

VIM-2 的突变分析揭示了金属β-内酰胺酶稳定性和折叠的关键决定因素。

Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.

机构信息

Dipartimento di Biologia Molecolare, Università di Siena, Policlinico Le Scotte, II piano, V lotto, Viale Bracci 1, I-53100 Siena, Italy.

出版信息

Antimicrob Agents Chemother. 2010 Aug;54(8):3197-204. doi: 10.1128/AAC.01336-09. Epub 2010 May 24.

DOI:10.1128/AAC.01336-09
PMID:20498317
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2916320/
Abstract

Metallo-beta-lactamase (MBL)-producing bacteria are emerging worldwide and represent a formidable threat to the efficacy of relevant beta-lactams, including carbapenems, expanded-spectrum cephalosporins, and beta-lactamase inactivator/beta-lactam combinations. VIM-2 is currently the most widespread MBL and represents a primary target for MBL inhibitor research, the clinical need for which is expected to further increase in the future. Using a saturation mutagenesis approach, we probed the importance of four residues (Phe-61, Ala-64, Tyr-67, and Trp-87) located close to the VIM-2 active site and putatively relevant to the enzyme activity based on structural knowledge of the enzyme and on structure-activity relationships of the subclass B1 MBLs. The ampicillin MIC values shown by the various mutants were affected very differently depending on the randomized amino acid position. Position 64 appeared to be rather tolerant to substitution, and kinetic studies showed that the A64W mutation did not significantly affect substrate hydrolysis or binding, representing an important difference from IMP-type enzymes. Phe-61 and Tyr-67 could be replaced with several amino acids without the ampicillin MIC being significantly affected, but in contrast, Trp-87 was found to be critical for ampicillin resistance. Further kinetic and biochemical analyses of W87A and W87F variants showed that this residue is apparently important for the structure and proper folding of the enzyme but, surprisingly, not for its catalytic activity. These data support the critical role of residue 87 in the stability and folding of VIM-2 and might have strong implications for MBL inhibitor design, as this residue would represent an ideal target for interaction with small molecules.

摘要

金属β-内酰胺酶(MBL)产生菌在全球范围内不断出现,对相关β-内酰胺类药物(包括碳青霉烯类、扩展谱头孢菌素类和β-内酰胺酶抑制剂/β-内酰胺类联合制剂)的疗效构成了严重威胁。VIM-2 是目前最为广泛流行的 MBL,也是 MBL 抑制剂研究的主要靶标,预计未来对 MBL 抑制剂的临床需求将会进一步增加。本研究采用饱和突变技术,针对紧邻 VIM-2 活性中心且根据该酶结构知识和亚类 B1 MBLs 的结构-活性关系推测与酶活性相关的四个残基(Phe-61、Ala-64、Tyr-67 和 Trp-87)的重要性进行了探究。根据各种突变体的氨苄青霉素 MIC 值,随机氨基酸位置对突变体的影响差异非常大。64 位似乎对取代具有较强的耐受性,动力学研究表明,A64W 突变并未显著影响底物水解或结合,这与 IMP 型酶有很大不同。Phe-61 和 Tyr-67 可以被多种氨基酸取代,而氨苄青霉素 MIC 值不受显著影响,但相比之下,Trp-87 对氨苄青霉素耐药性至关重要。对 W87A 和 W87F 变体的进一步动力学和生化分析表明,该残基显然对酶的结构和正确折叠很重要,但令人惊讶的是,对其催化活性没有影响。这些数据支持了 87 位残基在 VIM-2 稳定性和折叠中的关键作用,并且可能对 MBL 抑制剂设计具有重要意义,因为该残基将成为与小分子相互作用的理想靶标。

相似文献

1
Mutational analysis of VIM-2 reveals an essential determinant for metallo-beta-lactamase stability and folding.VIM-2 的突变分析揭示了金属β-内酰胺酶稳定性和折叠的关键决定因素。
Antimicrob Agents Chemother. 2010 Aug;54(8):3197-204. doi: 10.1128/AAC.01336-09. Epub 2010 May 24.
2
Elucidating the role of Trp105 in the KPC-2 β-lactamase.阐明 Trp105 在 KPC-2 β-内酰胺酶中的作用。
Protein Sci. 2010 Sep;19(9):1714-27. doi: 10.1002/pro.454.
3
Role of Residues W228 and Y233 in the Structure and Activity of Metallo-β-Lactamase GIM-1.残基W228和Y233在金属β-内酰胺酶GIM-1的结构与活性中的作用
Antimicrob Agents Chemother. 2015 Dec 7;60(2):990-1002. doi: 10.1128/AAC.02017-15. Print 2016 Feb.
4
Analysis of the functional contributions of Asn233 in metallo-β-lactamase IMP-1.分析金属-β-内酰胺酶 IMP-1 中 Asn233 的功能贡献。
Antimicrob Agents Chemother. 2011 Dec;55(12):5696-702. doi: 10.1128/AAC.00340-11. Epub 2011 Sep 6.
5
Elucidating the Role of Residue 67 in IMP-Type Metallo-β-Lactamase Evolution.阐明67位残基在IMP型金属β-内酰胺酶进化中的作用。
Antimicrob Agents Chemother. 2015 Dec;59(12):7299-307. doi: 10.1128/AAC.01651-15. Epub 2015 Sep 14.
6
Exploring the Role of Residue 228 in Substrate and Inhibitor Recognition by VIM Metallo-β-lactamases.探索228位残基在VIM金属β-内酰胺酶识别底物和抑制剂中的作用
Biochemistry. 2015 May 26;54(20):3183-96. doi: 10.1021/acs.biochem.5b00106. Epub 2015 May 12.
7
Biochemical characterization of New Delhi metallo-β-lactamase variants reveals differences in protein stability.新德里金属β-内酰胺酶变体的生化特性揭示了蛋白质稳定性的差异。
J Antimicrob Chemother. 2015 Feb;70(2):463-9. doi: 10.1093/jac/dku403. Epub 2014 Oct 16.
8
Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance.磺酰胺杂芳基羧酸作为有前途的金属β-内酰胺酶抑制剂,用于控制细菌碳青霉烯类耐药性。
mBio. 2020 Mar 17;11(2):e03144-19. doi: 10.1128/mBio.03144-19.
9
Structural and biochemical evidence that a TEM-1 beta-lactamase N170G active site mutant acts via substrate-assisted catalysis.结构和生化证据表明 TEM-1 型β-内酰胺酶 N170G 活性部位突变体通过底物辅助催化起作用。
J Biol Chem. 2009 Nov 27;284(48):33703-12. doi: 10.1074/jbc.M109.053819. Epub 2009 Oct 6.
10
The interaction of the azetidine thiazole side chain with the active site loop (ASL) 3 drives the evolution of IMP metallo-β-lactamase against tebipenem.氮杂环丁烷噻唑侧链与活性位点环(ASL)3 的相互作用推动 IMP 金属-β-内酰胺酶对抗替比培南的进化。
Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0068724. doi: 10.1128/aac.00687-24. Epub 2024 Jul 18.

引用本文的文献

1
Emergence of Carbapenem-resistant Clinical Isolates of Species.该物种对碳青霉烯类耐药临床分离株的出现。
Juntendo Iji Zasshi. 2022 Jun 9;68(3):200-207. doi: 10.14789/jmj.JMJ21-0057-R. eCollection 2022.
2
Molecular and Kinetic Characterization of MOX-9, a Plasmid-Mediated Enzyme Representative of a Novel Sublineage of MOX-Type Class C β-Lactamases.MOX-9 的分子和动力学特征,一种代表新型 MOX 型 C 类β-内酰胺酶亚谱系的质粒介导的酶。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0059522. doi: 10.1128/aac.00595-22. Epub 2022 Aug 30.
3
Emergence and Evolution of Unique Plasmids Harboring and in Multidrug-Resistant Providencia rettgeri.多重耐药普罗威登斯菌中携带 和 的独特质粒的出现和进化。
Microbiol Spectr. 2022 Aug 31;10(4):e0120422. doi: 10.1128/spectrum.01204-22. Epub 2022 Jul 6.
4
Identification of a Stable Chromosomal Tandem Multicopy of , a New Carbapenemase.鉴定一种新的碳青霉烯酶——的稳定染色体串联多拷贝。
J Bacteriol. 2022 Jul 19;204(7):e0008822. doi: 10.1128/jb.00088-22. Epub 2022 Jun 27.
5
Detection and Characterization of VIM-52, a New Variant of VIM-1 from a Klebsiella pneumoniae Clinical Isolate.检测和特征分析肺炎克雷伯菌临床分离株中的 VIM-52,一种新型 VIM-1 变体。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0266020. doi: 10.1128/AAC.02660-20. Epub 2021 Aug 9.
6
Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design.金属β-内酰胺酶在多药耐药时代:从结构和机制到进化、传播和抑制剂设计。
Chem Rev. 2021 Jul 14;121(13):7957-8094. doi: 10.1021/acs.chemrev.1c00138. Epub 2021 Jun 15.
7
Emergence of Carbapenem-Resistant Providencia rettgeri and Producing IMP-Type Metallo-β-Lactamase in Japan.日本出现耐碳青霉烯类阴沟肠杆菌和产生 IMP 型金属β-内酰胺酶。
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.00382-20.
8
Virtual screening identifies broad-spectrum β-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemases.虚拟筛选鉴定出对临床相关丝氨酸和金属碳青霉烯酶具有活性的广谱β-内酰胺酶抑制剂。
Sci Rep. 2020 Jul 29;10(1):12763. doi: 10.1038/s41598-020-69431-y.
9
4-(-Alkyl- and -Acyl-amino)-1,2,4-triazole-3-thione Analogs as Metallo-β-Lactamase Inhibitors: Impact of 4-Linker on Potency and Spectrum of Inhibition.4-(-烷基-和-酰基-氨基)-1,2,4-三唑-3-硫酮类似物作为金属β-内酰胺酶抑制剂:4-连接子对抑制效力和谱的影响。
Biomolecules. 2020 Jul 23;10(8):1094. doi: 10.3390/biom10081094.
10
Gene Expression Modulates the Inflammatory Response of Human Macrophages to Escherichia coli.基因表达调节人巨噬细胞对大肠杆菌的炎症反应。
Infect Immun. 2020 Jul 21;88(8). doi: 10.1128/IAI.00018-20.

本文引用的文献

1
The zinc center influences the redox and thermodynamic properties of Escherichia coli thioredoxin 2.锌中心影响大肠杆菌硫氧还蛋白2的氧化还原和热力学性质。
J Mol Biol. 2009 Feb 13;386(1):60-71. doi: 10.1016/j.jmb.2008.11.046. Epub 2008 Dec 3.
2
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy.意大利首次针对革兰氏阴性病原体中获得性金属β-内酰胺酶的全国性调查。
Antimicrob Agents Chemother. 2008 Nov;52(11):4023-9. doi: 10.1128/AAC.00707-08. Epub 2008 Sep 22.
3
Transketolase and 2',3'-cyclic-nucleotide 3'-phosphodiesterase type I isoforms are specifically recognized by IgG autoantibodies in multiple sclerosis patients.转酮醇酶和I型2',3'-环核苷酸3'-磷酸二酯酶亚型可被多发性硬化症患者的IgG自身抗体特异性识别。
Mol Cell Proteomics. 2008 Dec;7(12):2337-49. doi: 10.1074/mcp.M700277-MCP200. Epub 2008 Jul 31.
4
High rates of metallo-beta-lactamase-producing Klebsiella pneumoniae in Greece--a review of the current evidence.希腊产金属β-内酰胺酶肺炎克雷伯菌的高发生率——当前证据综述
Euro Surveill. 2008 Jan 24;13(4):8023.
5
TEM-1 beta-lactamase folds in a nonhierarchical manner with transient non-native interactions involving the C-terminal region.
Biochemistry. 2008 Jan 29;47(4):1186-93. doi: 10.1021/bi701927y. Epub 2008 Jan 3.
6
The three-dimensional structure of VIM-2, a Zn-beta-lactamase from Pseudomonas aeruginosa in its reduced and oxidised form.来自铜绿假单胞菌的锌β-内酰胺酶VIM-2还原态和氧化态的三维结构。
J Mol Biol. 2008 Jan 18;375(3):604-11. doi: 10.1016/j.jmb.2007.11.012. Epub 2007 Nov 13.
7
Crystallographic investigation of the inhibition mode of a VIM-2 metallo-beta-lactamase from Pseudomonas aeruginosa by a mercaptocarboxylate inhibitor.对来自铜绿假单胞菌的VIM-2金属β-内酰胺酶受巯基羧酸盐抑制剂抑制模式的晶体学研究。
J Med Chem. 2007 Dec 27;50(26):6647-53. doi: 10.1021/jm701031n. Epub 2007 Dec 6.
8
Inference of macromolecular assemblies from crystalline state.从晶体状态推断大分子组装体
J Mol Biol. 2007 Sep 21;372(3):774-97. doi: 10.1016/j.jmb.2007.05.022. Epub 2007 May 13.
9
Carbapenemases: the versatile beta-lactamases.碳青霉烯酶:多功能β-内酰胺酶
Clin Microbiol Rev. 2007 Jul;20(3):440-58, table of contents. doi: 10.1128/CMR.00001-07.
10
Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.不动杆菌属和铜绿假单胞菌的多药耐药机制。
Clin Infect Dis. 2006 Sep 1;43 Suppl 2:S49-56. doi: 10.1086/504477.